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Vision
Finland will have in place a multidisciplinary national 
network of pharmaceutical sector stakeholders to  
produce and disseminate evidence-based, objective 
and reliable information to healthcare professionals  
and the public.
Mission
Medicines information promotes the rational use of  
medicines among the population and thus maintains  
and improves the health of the Finnish population. 
RATIONAL USE OF MEDICINES THROUGH 
INFORMATION AND GUIDANCE
SUMMARY
STRATEGIC GOALS AND OBjECTIvES 2012–2020: 
1 To establish a multidisciplinary medicines information network in Finland.
 • Establishing a national medicines information  
  network.
 • Incorporating research and follow-up  
  in medicines information activities. 
 • Participating in international initiatives.
2 To ensure that healthcare professionals utilise reliable information sources and   
  services. 
 • Increasing awareness of reliable information sources.
 • Improving the accessibility and usability of medicines  
  information.
 • Utilising experts and existing specialist services. 
3 To ensure a high level medicines expertise and multidisciplinarity in healthcare.
 • Improving medicines expertise and developing  
  training in medication counselling. 
 • In basic and complementary education emphasising  
  a patient-centred attitude, a multidisciplinary  
  approach and support for patient self-management.
4 To base medication counselling on   national guidelines and local agreements.  
 • Harmonising the provision of medication  
  counselling in healthcare.
 • Using medicines information to support the  
  provision of pharmacotherapy in various settings. 
 • Ensuring medication counselling in self-care.
5 To ensure that medicine users utilise  reliable information sources and  
  services.
 • Ensuring the availability of reliable medicines  
  information. 
 • Promoting the readability and usability  
  of package leaflets. 
 • Producing medicines information in minority  
  languages and for other special groups.
 • Increasing the use of information and communica-  
  tions technology to disseminate medicines information. 
 
6 To achieve a high level of health literacy among the general public.
 • Promoting health literacy among children and adults.
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6In Finland, medicines information and its dissemination 
have been discussed since the 1970s. Physicians have 
traditionally been responsible for advising patients on the 
use of medicines. In the 1980s, however, pharmacists 
were given greater responsibility for ensuring that medi-
cine users were aware of the correct and safe use of 
each particular medicine. The first computer-based direc-
tions designed to increase such awareness were devel-
oped at roughly the same time. Medicines information 
activities have expanded considerably since then. 
From a citizen and patient perspective, medicines infor-
mation can be considered to be a right, and it should be 
an essential component of the rational use of medicines. 
The patient’s own role and active participation in main-
taining health and treating diseases have been empha-
sised in recent years. Medicines information activities 
have also striven to ensure that medicines are used ef-
fectively, safely and economically. The healthcare system 
is placing greater emphasis on multidisciplinary coopera-
tion in which the patient has a central role. To ensure 
good collaboration, it is essential that everyone has an 
adequate and sound knowledge base to allow them to 
participate in the discussions and decision-making.
Patient access to information has increased greatly in 
recent years. Healthcare professionals have become 
more active, a variety of medication guides have gained 
wider usage, and the Internet and social media are be-
coming increasingly important information sources. The 
wealth of these formal and informal sources presents 
challenges for patients and healthcare professionals 
alike. It is now more important than ever to find objective 
and reliable information and assess existing information.
INTRODUCTION
At the European level, too, medicines information has 
been given considerable attention in recent years. The 
Pharmaceutical Forum of the European Commission 
compiled guidelines on the quality of medicines informa-
tion available to patients and on disseminating informa-
tion in the various healthcare sectors. The European 
Parliament has witnessed at times quite heated debate 
on access to medicines information and on disseminating 
medicines information to patients. The concerns expressed 
have included to what extent patients’ needs are being 
addressed and whether citizens stand on equal ground in 
the different EU member states. Information quality, over-
sight and access to objective information are matters 
where the opinions of stakeholders have differed to a 
great extent.
The dissemination of medicines information in Finland 
has made considerable progress over the past decades. 
In spite of this, the needs of patients and healthcare pro-
fessionals for reliable and objective information are not 
always met. The Medicines Information Strategy therefore 
aims to address the state of medicines information activi-
ties as a whole: where are we now, where do we want to 
go and which goals do we wish to achieve during the next 
decade? Stakeholders have actively participated in com-
piling the Strategy, and this collaboration will continue 
when the new medicines information network is estab-
lished. In line with its duties, Fimea will compile, evaluate 
and disseminate information on medicines to the public, to 
healthcare professionals and to others who are in need of 
medicines information, as determined in the Medicines 
Policy 2020 compiled by the Ministry of Social Affairs  
and Health.
Sinikka Rajaniemi
Director General 
Finnish Medicines Agency Fimea 
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Physician or a nurse with the 
postgraduate qualification that 
entitles registered nurses to a  
limited right to prescribe medicines
Nurse, practical nurse
Pharmacist
Seeking  
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FROM MEDICINES INFORMATION TO 
THE RATIONAL USE OF THE MEDICINE
Product-specific information:
Summary of Product Characteristics 
Package leaflet
Therapeutic value of a medicinal product
Treatment guidelines
Assessing the therapeutic and economic 
value of the medicine
Selecting pharmacotherapy  
for a specific patient
Medication counselling
Patient advice and guidance
Dispensing the medicine and  
providing medication counselling
Treatment monitoring:  
benefits and adverse effects
PATIENT:
8The Finnish Medicines Agency Fimea has the statutory 
duty of compiling, evaluating and disseminating informa-
tion on medicines to the public, to social services and 
healthcare professionals and to others who need medi-
cines information (Act on the Finnish Medicines Agency, 
593/2009). It must carry out these duties in collaboration 
with stakeholders in the field, such as public authorities, 
universities, research institutions and social services and 
healthcare units. Fimea is also responsible for the long-
term planning and coordination of medicines information 
activities. It has been charged with compiling a national 
medicines information strategy that addresses the work 
being performed by the existing stakeholders, while also 
identifying any deficiencies (Government proposal 
74/2009). 
This Medicines Information Strategy has been produced 
on the basis of discussions with stakeholders and state-
ments received on an initial draft strategy (Annex 1). 
Experts from the Fimea Assessment of Pharmacothera-
pies Process as well as from the Pharmacovigilance Unit 
participated in compiling the strategy. The person respon-
sible for the Strategy compilation was Katri Hämeen-
Anttila, Development Manager. The Strategy describes 
best practices, deficiencies and challenges with respect 
to current medicines information activities. Since medi-
cines information is closely linked to many pharmaceuti-
cal functions, the Strategy provides an extensive descrip-
tion of the current status of medicines information activi-
ties, from ensuring adequate medicines expertise among 
healthcare professionals to developing health literacy 
among the public. 
The Strategy proposes various measures and empha-
sises the need to establish a medicines information net-
work in Finland. The network would recommend which 
proposals are to be collaboratively developed. It would 
also determine the goals of various interventions and the 
ways in which their achievement will be monitored. The 
network may also identify a need for completely novel 
interventions. The Strategy will be reassessed and up-
dated at regular intervals. 
The proposals concern very different magnitudes of 
scale. Some require significant additional resources to be 
feasible, while others can probably be carried out with 
existing resources by increasing collaboration and discus-
sion. However, this requires commitment on the part of 
stakeholders as well as a willingness to incorporate the 
Strategy in their own activities. Fimea has also identified 
medicines information development needs related to its 
own activities and will seek to achieve progress on these 
in its future operations.
Vision
Finland will have in place a multidisciplinary national 
network of pharmaceutical sector stakeholders to pro-
duce and disseminate evidence-based, objective and 
reliable information to healthcare professionals and the 
public.
Mission
Medicines information promotes the rational use of medi-
cines among the population and thus maintains and im-
proves the health of the Finnish population.
BACKGROUND
9STRATEGIC GOALS AND OBjECTIvES 2012–2020: 
1 To establish a multidisciplinary medicines information network in Finland.
 • Establishing a national medicines information  
  network.
 • Incorporating research and follow-up  
  in medicines information activities. 
 • Participating in international initiatives.
2 To ensure that healthcare professionals utilise reliable information sources and   
  services. 
 • Increasing awareness of reliable information sources.
 • Improving the accessibility and usability of medicines  
  information.
 • Utilising experts and existing specialist services. 
3 To ensure a high level medicines expertise and multidisciplinarity in healthcare.
 • Improving medicines expertise and developing  
  training in medication counselling. 
 • In basic and complementary education emphasising  
  a patient-centred attitude, a multidisciplinary  
  approach and support for patient self-management.
4 To base medication counselling on   national guidelines and local agreements.  
 • Harmonising the provision of medication  
  counselling in healthcare.
 • Using medicines information to support the  
  provision of pharmacotherapy in various settings. 
 • Ensuring medication counselling in self-care.
5 To ensure that medicine users utilise  reliable information sources and  
  services.
 • Ensuring the availability of reliable medicines  
  information. 
 • Promoting the readability and usability  
  of package leaflets. 
 • Producing medicines information in minority  
  languages and for other special groups.
 • Increasing the use of information and communica-  
  tions technology to disseminate medicines information. 
 
6 To achieve a high level of health literacy among the general public.
 • Promoting health literacy among children and adults.
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GOAL 1.
TO ESTABLISH  
A MULTIDISCIPLINARY  
MEDICINES INFORMATION 
NETwORK IN FINLAND.
Establishing a national medicines  
information network.
A wide range of bodies produce medicines information in 
Finland. while this represents an important resource, it 
can cause duplication of work and produce information 
that is fragmented. One of the goals of the Medicines 
Policy 2020 is to increase both national and international 
collaboration in the production of medicines information 
and associated services and in the evaluation of their 
effectiveness (Ministry of Social Affairs and Health 2011a).
In the proposed model for a medicines information net-
work, a Medicines Information Coordination Group ap-
pointed by Fimea will carry out development projects and 
MEDICINES INFORMATION
COORDINATION GROUP
Communications team
Education working group Research working group
The Medicines Information Forum 
– users and producers
Development 
project
Development 
project
Development 
project
Development 
project
Development 
project
monitor their progress. The group will also assess devel-
opment projects launched or commissioned by stakehold-
ers. A communications team will assist with the projects 
assessed. The communications team will involve commu-
nications expertise from various stakeholders and repre-
sentatives of special groups such as sign language users. 
Development projects bring forth concrete development 
needs, which will be put forward at meetings titled The 
Medicines Information Forum – users and producers. The 
network will also include education and research working 
groups (Figure 1). Fimea will be in charge of coordinating 
the activities of the network. Each stakeholder will decide 
independently on the extent to which they commit themselves 
to the network and participate in development projects.
Figure 1. The medicines information network. Current proposal. 
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Medicines Information Forum – users and producers  
• This biannual multidisciplinary forum will bring together 
the users and producers of medicines information. The 
forum will foster wide-ranging debate on the current sta-
tus and challenges of developing medicines information 
and on the need for new development projects.
Medicines Information Coordination Group
• The group will consist of representatives of key  
medicines information stakeholders and meet at least 
once a year (more often at the outset). The group will:
- promote and coordinate the development of  
medicines information in Finland
- make proposals for the prioritisation of development 
projects presented in this strategy
- monitor development projects and comment on  
their progress
- coordinate research related to medicines information 
- promote international collaboration.
Education and research working groups
• The education working group will be a forum for teachers 
working at vocational institutions, polytechnics, universi-
ties and complementary education units. It will develop 
solutions aimed at promoting a multidisciplinary approach 
and medicines information activities in basic and com-
plementary education. The needs of working life will be 
taken into account in its activities.
• The research working group will include stakeholders 
who carry out research on medicines information and 
promote research and collaboration in this field. The 
research working group will also determine the most 
important research areas and topics related to medi-
cines information.
Development project committees
• An operative committee will be established for a fixed 
term for each development project. It can be established 
on the initiative of the Medicines Information Coordination 
Group or of a stakeholder party.  
All stakeholders will fund their own participation in  
the network. Development projects may also apply  
for external funding.  
Proposal:
• Establish a medicines information network in order to 
increase cooperation, a more systematic approach and 
greater multidisciplinarity in developing medicines infor-
mation activities and to promote collaboration between 
the public and private sectors.
Incorporating research and follow-up in 
medicines information activities.
At the start of the network’s activities, concrete existing 
medicines information tools and development projects 
designed for healthcare professionals will be collected 
with a view to promoting their use. Proven medicines 
information tools and best practices can be shared and 
disseminated, for example via the Innokylä Innovillage. 
The Innokylä InnoVillage (www.innokyla.fi) is an innova-
tion community for social services and healthcare stake-
holders and developers. It offers, among other things, 
forums and online tools for the creation and introduction 
of new practices.
The activities of the medicines information network must 
be based on research and existing best practices. Activi-
ties can thus be developed in the right direction, and 
medicines information can be produced in a targeted 
manner. It is important that the research and expertise of 
universities and polytechnics are utilised in the network’s 
activities. when evaluating the different aspects of medi-
cines information, it is also necessary to assess the  
opportunities to utilise national studies conducted at  
regular intervals. For instance, the survey on Health  
Behaviour and Health among the Finnish Adult Population 
of the Finnish National Institute for Health and welfare 
has in previous years contained questions on medicines 
information (e.g. Närhi and Helakorpi 2007). 
To monitor medicines information activities, the medicines 
information indicators created by the Medicines Policy 
2020 indicator working group will be further developed. 
Proposal:
• To direct the activities of the medicines information  
network, the following will be assessed:
- the need for information among healthcare  
professionals in the different sectors
- the need for information among patients and  
medicine users
- the effectiveness of medication counselling  
and guidance.
Participating in international initiatives.
The Pharmaceutical Forum of the European Commission 
(2005–2008) gathered together best practices and avail-
able tools in order to improve the medicines information 
available to patients (High Level Pharmaceutical Forum 
2008). The Pharmaceutical Forum also issued recom-
mendations on the core quality principles for medicines 
information to patients and the best ways of disseminat-
ing information in the different healthcare sectors. The 
Pharmaceutical Forum emphasises the need to share 
best practices among the different European Union member 
states. International models and tools should be assessed 
with regard to their applicability in Finland, and their feasi-
bility in developing medicines information should be eval-
uated. The medicines information network should also 
take an active role in promoting Finnish best practices for 
the European Commission and other member states. The 
aim should be uniform medicines information throughout 
the European Union.
Proposal:
• Assess the applicability of international models and 
medicines information tools for use in Finland.
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GOAL 2.
TO ENSURE THAT HEALTH-
CARE PROFESSIONALS  
UTILISE RELIABLE  
INFORMATION SOURCES 
AND SERvICES.
Increasing awareness of  
reliable information sources.
A number of stakeholders produce medicines information 
in Finland, and there are numerous sources of medicines 
information (Annex 2). There is a wealth of information 
on medicinal substances and products in particular. There 
is also plenty of information on the role of pharmacothera-
pies in the treatment of different medical conditions. The 
bodies producing and disseminating such information are, 
however, outnumbered by those producing information on 
a specific product. The most important information chan-
nels are the Current Care guidelines produced by the 
Finnish Medical Society Duodecim and the extensive 
medical database Terveysportti. It is important to increase 
awareness of existing sources of information and to  
encourage their use. One way to achieve this is by train-
ing healthcare professionals to use them. In Finland, the 
availability of medicines information in Swedish is much 
poorer than in Finnish.
Few healthcare professionals have time to gain a detailed 
insight into the characteristics and interactions of medi-
cines or to study the differences between medicines with 
similar mechanisms of action. Assessments and summa-
ries are essential in developing medicines information and 
will continue to be so in the future. New information should 
be incorporated into commonly used databases or portals. 
In future, pharmacotherapies will be increasingly individu-
alised, and this will increase the need for information. 
New medicines are an area where the need to obtain 
properly evaluated, up-to-date information comparing the 
product with other medicines and treatments is particu-
larly great. Medicines information produced by pharma-
ceutical companies mainly focuses on the features of a 
specific product. However, pharmaceutical companies 
gain a substantial amount of information on their products 
during pharmaceutical development, research and the 
post-marketing surveillance of safety and effectiveness.  
It is important that such information is published. Compa-
nies disseminate product-specific information to health-
care professionals via medical information services,  
manuals, training events and other channels. 
Information management during a crisis is an area that 
needs particular attention in Finland. There is currently  
no system that would allow a message to be sent to all 
healthcare professionals during the same day. 
Proposals:
• Produce summaries of pharmacotherapies  
(such as the Kapseli publication series).
• Produce evaluations and summaries of the therapeutic 
and economic value of medicines for healthcare  
professionals and patients. Encourage greater  
utilisation of evaluated evidence. 
• Improve the availability of medicines information in 
Swedish for healthcare professionals. 
• Establish an effective information management system 
for crisis situations and pharmacovigilance-related  
information to ensure that all healthcare professionals 
can be contacted during the same day.
Improving the accessibility and usability of 
medicines information.
The amount of available medicines information is large, 
but its fragmented nature and poor accessibility may 
cause problems. Factors such as shortage of time, poor 
skills and the fees charged may also hamper the use of 
information sources. Successful pharmacotherapy and 
thus patient safety can be promoted by means of auto-
matic clinical decision support systems integrated into 
electronic patient records systems. Novel technological 
approaches will also improve the accessibility and user-
friendliness of medicines information in the future. 
Summaries of Product Characteristics (SPCs) vary in 
terms of their content, and the terms used may also differ 
from one medicinal product to the next, for instance  
because of the different marketing authorisation practices 
employed in different countries. This affects the user-
friendliness of SPCs. Harmonisation of SPC texts is  
ongoing in the European Union, but progress is slow. 
There may also be problems in the accessibility of SPCs. 
It may sometimes take time before information on a specific 
medicine is available on the Fimea website. If a medicine 
has been approved via the centralised EU procedure,  
its SPC and package leaflet are only available on the  
European Medicines Agency (EMA) website. 
It would also be important to compile and publish an 
impartial medicines information formulary based on generic 
names that would give suggestions for the choice of an 
appropriate medicine and gather together the most impor-
tant general information about different medicinal sub-
stances irrespective of the SPCs used by different manu-
facturers. The need for such a formulary is particularly 
evident as new biosimilars are being launched.  
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Proposals:
• Ensure through basic and complementary education 
that healthcare professionals are aware of the various 
information sources and databases and are able to  
use them.
• Develop electronic clinical decision support systems  
and integrate them into existing information systems. 
• Ensure easy access to SPCs. Improve the quality of 
SPCs in the EU.
• Produce a medicines information formulary in Finnish 
based on generic names.
Utilising experts and existing specialist 
services. 
In their work, healthcare professionals encounter difficult 
questions related to pharmacotherapies, which they first 
discuss with their colleagues. The most challenging ques-
tions and problem situations for which local resources are 
insufficient should be presented to experts specialising in 
pharmacotherapy. Unfortunately, the availability of such 
services is restricted. 
Medical specialists in Clinical Pharmacology and  
Pharmacotherapy are able to solve challenging patient-
specific problems irrespective of where the patient is 
being treated. They provide consultation services to  
support the treatment of both inpatients and outpatients 
and participate in producing information on medicines 
and pharmacotherapy. To improve the safety of pharma-
cotherapy and patient safety, it is important to utilise these 
expert resources to the full and use them to address the 
most challenging problems in pharmacotherapy. There are 
about 30 medical specialists in Clinical Pharmacology 
and Pharmacotherapy in Finland. 
It is also important to draw on the expertise of hospital 
and health centre pharmacists in the treatment provided 
by healthcare units. Pharmacists working in hospital phar-
macies and health centre dispensaries, as well as ward 
pharmacists, are asked about matters relating to the 
pharmaceutical properties of medicines in particular. 
However, they also address patient-specific problems 
in pharmacotherapy. The expertise of ward pharmacists 
could be utilised more extensively for instance in provid-
ing pharmacotherapy-related training for other personnel. 
ward pharmacists may also review medication, partici-
pate in patients’ admission interviews and provide medi-
cation counselling. Those with a formal specialisation 
may also carry out comprehensive medication reviews. 
ward pharmacists’ services are currently available in at 
least 35 hospitals and health centres and on more than 
200 wards. There are about 150 ward pharmacists, some 
of whom work in more than one ward. 
Pharmacists with a formal specialisation in comprehen-
sive medication reviews are a resource that could be 
utilised more widely in hospital and outpatient medicines 
information work (Annex 3). The total number of pharma-
cists formally specialised for this is currently about 150.
Healthcare professionals with queries may also consult 
online and telephone services such as the HUS (Hospital 
District of Helsinki and Uusimaa) and TYKS (Turku Uni-
versity Hospital) Clinical Pharmacology consultation ser-
vices; the National Pharmaceutical Information Centre 
KLIK, owned by the Pharmaceutical Information Centre 
and the University of Eastern Finland; the University 
Pharmacy information services; the HUS Poison Informa-
tion Centre; and the HUS Teratology Information Service. 
Networking and collaboration between these institutions 
would reduce overlapping in the provision of services and 
improve the potential to utilise all stakeholders’ expertise. 
In networking, it is important to assess resources and the 
distribution of tasks, e.g. how the resources of medical 
specialists in Clinical Pharmacology can best be used to 
address the most challenging problems in pharmacother-
apy. It is also important to increase awareness of medi-
cines information services. Primary care units, for in-
stance, should be aware of who to contact if they have 
problems concerning medicines information. 
The same medicines information services also respond  
to queries submitted by patients. From a population and 
patient perspective, it is important that medicines informa-
tion services can also be contacted by e-mail and that 
they are active in social media, a route often used by 
medicine users to seek help for their problems. Providing 
information to the population in crisis situations, e.g. in 
the event of a pandemic, should also be an integral part 
of medicines information activities. Special groups should 
also be taken into consideration, particularly in crisis 
situations.  
Proposals:  
• Evaluate opportunities for networking and coordination 
of activities between the stakeholders currently  
providing medicines information services. 
• Evaluate and monitor the quality of medicines  
information disseminated by stakeholders  
providing medicines information services.
• Increase awareness of and collaboration between 
Clinical Pharmacology and Clinical Pharmacy  
services.
- Develop Clinical Pharmacology and Clinical  
Pharmacy services and ensure access to them  
everywhere in Finland, for instance by creating  
a network-type consultation service for healthcare 
professionals.
- Shift the focus of ward pharmacy activities from 
medicine logistics towards clinical pharmacy:  
medication review and medication counselling for 
patients (e.g. admission interview, review of admitted 
patients’ medication, medication counselling on 
discharge together with a physician and a nurse).
• Step up collaboration in producing hospital-specific 
internal Standard Operating Procedures (SOPs) and in 
disseminating these SOPs and best practices in phar-
macotherapy. Opportunities to utilise guidelines and 
practices from other countries should also be evaluated.
14
TO ENSURE A HIGH LEvEL 
OF MEDICINES EXPERTISE 
AND MULTIDISCIPLINARITY 
IN HEALTHCARE.
Improving medicines expertise and developing 
training in medication counselling. 
Healthcare professionals are patients’ primary source of 
information related to medical conditions and their phar-
macotherapy (Närhi 2007, Närhi and Helakorpi 2007). An 
adequate pharmacotherapy knowledge base is essential 
for all counselling. The development of pharmacotherapy-
related training requires different perspectives and fo-
cuses on different aspects of pharmacotherapy depend-
ing on the group of professionals in question. The needs 
of working life must be taken into account in the teaching 
contents of both basic and complementary education. 
Development should particularly focus on counselling for 
pharmacotherapies for key public health concerns such 
as cardiovascular disease and diabetes. The availability 
of generic products (including biosimilars) means that 
understanding of generic information is important for all 
professionals involved in pharmacotherapy. This includes 
both the recognition of generic names instead of brand 
names and an understanding of potential differences 
between generic products. To avoid misunderstanding, 
medicines information should primarily be based on ge-
neric names. Professionals and patients alike may have 
trouble grasping the several brand names and generic 
products available for a single medicinal substance.
In-house training has a major impact on how medication 
counselling is provided in practical situations. Areas cov-
ered may include information sources, SOPs and agreed 
medication counselling practices applicable to the unit in 
question. During a professional’s career, the development 
of professional expertise depends both on the unit in 
which the professional works and on his or her personal 
interests and opportunities to seek information (for in-
stance, independent selection and reading of professional 
literature, participation in training). Some licensed health-
care professionals providing pharmacotherapy and pro-
fessionals with a protected occupational title have their 
medicines expertise and skills evaluated according to 
their units’ pharmacotherapy plans, for instance with 
practical examinations and site-specific pharmacotherapy 
licences repeated every 2 to 5 years (Ministry of Social 
Affairs and Health 2006).
Physicians are well educated in the diagnosis and treat-
ment of medical conditions during their basic education, 
specialisation process and complementary education. 
Medical education provides teaching on patient-physician 
interaction, but less time is devoted to medication coun-
selling. Physicians also need further training in the critical 
assessment of research evidence and in the assessment 
of cost-effectiveness. It is also important to ensure that, in 
addition to product-specific information, physicians have 
access to comparative, impartial information on medicines.
The basic education of pharmacists focuses on medicinal 
substances and their effects in humans. It also provides 
good skills in providing patient-centred medication coun-
selling. Students practise their ability to apply theoretical 
knowledge in practical situations by means of medication 
counselling labs. This area is also addressed during stu-
dents’ traineeships at teaching pharmacies. Basic educa-
tion should pay more attention to clinical pharmacy skills 
and increasingly focus on the practical application of 
theoretical knowledge. As ward pharmacy activities  
increase, it is important that basic education puts a 
stronger emphasis on skills required in hospital work.
Graduating nurses must have adequate skills to carry  
out pharmacotherapy-related tasks in a safe and effective 
manner (Sulosaari et al. 2010). In Finland, this is ensured 
by issuing a Medication Passport, a tool used during 
nurses’ basic education courses. The extent and focus  
of medicines expertise depends on the unit in which the 
professional works (e.g. specialist healthcare unit, child 
and maternity welfare clinic, elderly care unit). Medicines 
expertise is playing an increasing role in the management 
of major public health concerns (e.g. hypertension, diabe-
tes, heart failure, kidney failure). In addition to technical 
dispensing, professionals must be aware of the effects 
and interactions of a medicine and be able to determine 
the need for monitoring. Legislative reforms have extended 
the duties of nurses and introduced a postgraduate quali-
fication that entitles registered nurses to a limited right to 
prescribe medicines (Ministry of Social Affairs and Health 
Decree on pharmaceutical prescriptions, 1088/2011). This 
demands sufficient professional experience after gradua-
tion together with additional studies, as stipulated in the 
Decree. The rights only apply to the nurse’s duties and 
site of employment.
Practical nurses have a basic qualification in social  
services and healthcare. They can work as healthcare 
professionals with a protected occupational title in health-
care units as well as in social services, e.g. in home care 
and residential institutions, and may assist in providing 
and monitoring pharmacotherapy. They work close to the 
client and their duties allow them to monitor the success 
of pharmacotherapy and its effects on each individual. It 
is important that this group of professionals has adequate 
skills. Practical nurses must be able to identify the adverse 
and unwanted effects of medicines and refer the client for 
assessment by a nurse or a physician. Requirements 
concerning the education of social services personnel are 
stipulated in the Decree on qualification requirements for 
social welfare professionals (608/2005). Social services 
GOAL 3.
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legislation does not provide for the participation of social 
services personnel in pharmacotherapy; this area is always 
the responsibility of healthcare professionals. Personnel 
qualifications and medicines expertise vary greatly, as do 
the local practices employed at different sites.
Proposals:
• Develop basic and complementary education for all 
professional groups.
- Develop existing syllabuses and ensure that physicians 
and other healthcare professionals are well prepared 
for reading, assessing and applying published  
research, treatment guidelines and assessments  
of the therapeutic and economic value of medicines.
- Increase the practical application of theoretical  
knowledge in clinical pharmacy teaching for  
pharmacy students.
- Further develop medicines expertise among nurses 
and ensure equal skills everywhere in Finland.
- Further develop practical nurses’ medicines expertise.
In basic and complementary education 
emphasising a patient-centred attitude,  
a multidisciplinary approach and support  
for patient self-management.
The National Archive of Health Information (KanTa) will 
emphasise the role of patients as experts in their own 
treatment. Everyone will be able to view their KanTa  
records online using the service entitled ‘viewing one’s 
personal information’. Patients will also decide which 
healthcare professionals are allowed to view their records. 
According to the Health Care Act (30 December 
2010/1326, section 24), local authorities are required  
to provide guidance to enhance patients’ treatment  
adherence and self-management.
Sound medicines expertise is essential for those working 
to support self-management, but this on its own is not 
enough. All healthcare professionals must, during their 
basic education, acquire sufficient basic knowledge and 
skills to provide medication counselling and support for 
self-management. Professionals must be able to take into 
account each patient’s wishes and attitudes with regard 
to medicine use and be able to discuss pharmacothera-
pies in a manner that is understandable for the individual 
in question. Complementary education, including specific 
formal qualification and specialisation programmes, must 
also provide knowledge and skills required in medication 
counselling and supporting self-management. It is impor-
tant that tools such as the National Institute for Health 
and welfare ROHTO network are utilised to promote 
healthcare professionals’ medicines expertise, ability to 
support self-management and a multidisciplinary approach.
with regard to supporting self-management, it is impor-
tant that different professionals complement and support 
each others’ work in terms of the medication counselling 
they provide. This requires multidisciplinary collaboration. 
Professionals first develop a positive attitude towards 
multidisciplinary collaboration during their basic education 
as they have shared courses with other groups of profes-
sionals and thus learn about each others’ competence. 
This facilitates multidisciplinary collaboration after gradu-
ation. All healthcare professionals must be aware of the 
importance of a multidisciplinary approach. 
Healthcare professionals, particularly physicians, play  
an important role in ensuring that general information 
from other sources is put in the right perspective with 
regard to each patient’s situation. Patients particularly 
wish to have balanced benefit and risk information  
(European Medicines Agency 2009). Medicines informa-
tion is often presented on a general level, and medicine 
users may have trouble applying it to their individual  
situation, even if the information is reliable.
Proposals:
• Ensure that basic and complementary education for  
all groups of professionals contain multidisciplinary 
courses. Teaching should address at least the  
following areas:
- a patient-centred approach and support for  
self-management
- tailored medication counselling
- a multidisciplinary approach
- increasing awareness of the competence of one’s  
own professional group among other groups of  
professionals.
• Consider special groups: Medicines information  
should be included in the basic and complementary 
education of sign language interpreters and  
interpreters working with immigrants.
16
TO BASE MEDICATION 
COUNSELLING ON  
NATIONAL GUIDELINES  
AND LOCAL AGREEMENTS.
Harmonising the provision of medication 
counselling in healthcare. 
According to the Health Care Act (30 December 
2010/1326), healthcare provision plans must include 
regional procedures for cooperation between the partici-
pating local authorities in health and welfare promotion 
and arrangements for the provision of healthcare services 
between the different parties involved. The plan must also 
include pharmaceutical services and the bodies responsi-
ble for them. The Medicines Policy 2020 also emphasises 
the importance of local agreements to promote collabora-
tion in pharmaceutical services (Ministry of Social Affairs 
and Health 2011a). It is also a good idea to include in the 
plan an agreement on medicines information activities. 
From a medicines information perspective, the patient’s 
arrival, transfer from one unit to another, and particularly 
the point of discharge are key contact points. Their 
smooth implementation with regard to matters such  
as the provision of medication counselling should be 
ensured and recorded in the healthcare provision plan. 
Patients have a statutory right to be informed about the 
significance of their treatment, any alternative forms of 
treatment and their effects and about other factors related 
to their treatment that are significant when treatment 
decisions are made (Act on the Status and Rights of 
Patients, 17 August 1992/785, section 5). A physician 
agrees with the patient on the treatment of the condition 
in question, prescribes medication and provides sufficient 
information on the therapeutic indication and use of the 
medicine. Registered nurses with the postgraduate quali-
fication that entitles them to a limited right to prescribe 
medicines provide medication counselling to the patients 
they treat. In pharmacies pharmacists instruct and advise 
patients on the safe and correct use of medicines while 
dispensing the products (Table 1). Personnel providing 
pharmacotherapy give information and practical advice 
on the use of medicines at the different stages of the 
pharmacotherapy process (Ministry of Social Affairs  
and Health 2006). 
To strengthen the patient’s role and enhance patients’ 
adherence, it is also important that patients are actively 
encouraged to ask about their medication, to report their 
wishes and to say which pharmacotherapy-related  
matters they find significant with regard to their life and 
quality of life. Each patient’s treatment is recorded in his 
or her health and care plan at the local health centre 
(Ministry of Social Affairs and Health Decree on patient 
documents 298/2009; Health Care Act, 30 December 
2010/1326). The health and care plan is an essential tool 
in monitoring the patient’s treatment as a whole.  
Table 1. The statutory duties of different professional 
groups in disseminating medicines information
Professional group and 
provision
Statutory duty
Physician 
Registered nurse with the 
postgraduate qualification 
that entitles them to  
a limited right to  
prescribe medicines 
Ministry of Social Affairs 
and Health Decree on 
pharmaceutical  
prescriptions, 1088/2011 
sections 8, 9 and 10
•  Prescribers must give the patient  
adequate information on the therapeu-
tic indication and use of the medicine. 
• If necessary, prescribers must cooper-
ate with the pharmaceutical personnel 
of the pharmacies that their patients 
commonly use in order to ensure that 
patients receive medication counselling 
and that their pharmacotherapy is safe, 
effective and cost-effective. 
• Prescribers must also take into  
consideration any guidelines  
concerning use.
Pharmacist
Medicines Act, 10 
December 2010/1112, 
section 57
•  When supplying medicinal products 
from pharmacies and subsidiary phar-
macies every effort must be made, 
through the advice and guidance of 
pharmaceutical personnel, to ensure 
that the users of the medicinal prod-
ucts are aware of the correct and safe 
use of the product. 
• In addition, medicinal product purchas-
ers must be given information about 
the medicinal product prices and about 
other factors affecting their choice of 
medicinal product.
• When supplying medicinal products 
from pharmacy service points and via 
online pharmacy services, pharma-
ceutical personnel must ensure that 
medicinal product purchasers have 
access to the advice and guidance 
of pharmaceutical personnel on the 
correct and safe use of medicines and 
to information about medicinal product 
prices and other factors affecting their 
choice of medicinal product. 
Increasing patient-centredness and promoting health are 
central goals of the working Health Centre programme 
(Ministry of Social Affairs and Health 2009). One of the 
main measures proposed in the programme is to develop 
the treatment and prevention of chronic diseases on the 
basis of the Chronic Care Model. According to the model, 
chronic disease management should move from a condition-
centred approach towards holistic, systematic assessment 
and support for the patient (wagner 1998). From the patient’s 
perspective, local action is very important. It is therefore 
essential to develop local multidisciplinary cooperation. 
At local level it is important to agree on ways to increase 
multidisciplinary cooperation to improve the follow-up and 
medication counselling of all chronic care patients. It is, 
for instance, important to agree on prescription renewal 
GOAL 4.
17
TREATMENT CHAIN FOR PATIENTS  
wITH A CHRONIC CONDITION
Starting pharmacotherapy
Physician or a nurse with the postgraduate 
qualification that entitles registered nurses  
to a limited right to prescribe medicines
● Diagnosing the condition
● Recommending pharmacotherapy and the  
 decision to start medication
● Choosing pharmacotherapy
● Informing the patient about the following:
 ● therapeutic indication, mechanism of action,   
  adverse effects, dosage, etc.
● Issuing the prescription
Specialist services, e.g. Clinical Pharmacology 
consultation services and comprehensive 
medication review
Providing pharmacotherapy in various settings, 
e.g. in home care or at a social welfare unit
E.g. practical nurses
● Basic details concerning administration  
 of the medicine
● Identifying any adverse effects of  
 pharmacotherapy
A wELL-INFORMED PATIENT wHO 
ADHERES TO THE THERAPY
Advice and guidance by a nurse 
● Practical implementation of pharmacotherapy
● Supporting adherence to therapy
Medication counselling at a pharmacy
Pharmacist
● Informing the patient about the following:
 ● mechanism of action, adverse effects, dosage,  
  matters related to taking the medicine, etc.
 • cost of the medicine
● Identifying any interactions
● Supporting adherence to therapy
Treatment monitoring
(meeting, phone call, email)
Physician, nurse, pharmacist
● Identifying the effects of pharmacotherapy  
 (benefits, adverse effects)
● Assessing the patient’s experiences
● Checking previous medicines information  
 and complementing it as necessary
● Ensuring successful pharmacotherapy
A new symptom, a patient with multiple 
comorbidities or starting a new medicine
Physician
● Diagnosing the condition
● Confirming that this is a new symptom or condition  
 and not an adverse effect caused by a medicine   
 currently used by the patient
● Identifying any interactions
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practices and associated medication counselling: when 
should pharmacists and nurses refer a patient to a physi-
cian instead of having the prescription renewed? Public 
health programmes are good examples of multidiscipli-
nary cooperation (Ministry of Social Affairs and Health 
1994, Finnish Diabetes Association 2000, Finnish Heart 
Association 2005, Haahtela et al. 2006). Pharmacies 
have contributed to national public health programmes  
by organising their own Pharmacies’ National Health 
Programmes: Pharmacy Asthma Programme, Pharmacy 
Diabetes Programme and Pharmacy Heart Programme. 
Thanks to public health programmes, public health expert 
networks have been established for primary care and 
pharmacies, which has significantly improved medication 
counselling for patients with a chronic condition. It is 
important to ensure that these expert bodies continue 
their work and further step up their collaboration.
Those with a chronic condition visit a pharmacy at least 
once every three months to obtain their medicines. These 
visits could be part of medication follow-up, which would 
support the first primary goal of the medicines policy, i.e. 
ensuring that the pharmaceutical service constitutes part 
of the social welfare and healthcare service systems 
(Ministry of Social Affairs and Health 2011a, Ministry of 
Social Affairs and Health 2011b). Medication counselling 
practices for those with a chronic condition should also  
be agreed locally.
Recording the medication counselling given at different 
stages of a patient’s treatment pathway could facilitate 
medication follow-up and indicate any areas that have not 
been discussed with the patient. The working Group on 
Development Needs Regarding Outpatient Pharmacy 
Operations suggests that quality standards for medication 
counselling should be defined to ensure that the statutory 
counselling given when dispensing a medicine is clearly 
distinguished from chargeable additional services  
(Ministry of Social Affairs and Health 2011b). Such quality 
standards would define the minimum requirements for 
medication counselling and help to harmonise practices 
across Finland. Quality standards should also address 
medication counselling for special groups. The need to 
document medication counselling should be considered 
while drafting the standards. 
Proposals:
• Increase collaboration between pharmacies and  
healthcare units and encourage more local agreements 
on monitoring long-term treatments. Medication  
counselling practices should also be agreed on. 
• Define quality and structural standards for medication 
counselling and assess the possibility to document  
and monitor medication counselling.
Using medicines information to support  
the provision of pharmacotherapy  
in various settings. 
Pharmacotherapy is provided in a very wide range of 
settings, for instance in institutions for the disabled, child 
protection institutions and various residential institutions 
such as residential homes for the elderly (Ministry of 
Social Affairs and Health 2006). Medicines may also be 
used at nurseries and schools. The personnel providing 
pharmacotherapy have very different educational back-
grounds, and some of them have no vocational health-
care education at all. 
To ensure safe pharmacotherapy, the unit-based pharma-
cotherapy plans compiled for each healthcare and social 
services unit must be followed (Ministry of Social Affairs 
and Health 2006). The plans cover the planning and  
implementation of pharmacotherapy at the unit as a whole, 
as well as the ways in which any deviations are monitored 
and reported. In their plans, each unit must also address 
the way in which medication counselling is arranged, 
since all patients, including those in institutional care, 
have the right to know what medicines they are given  
and what their use entails. The following key aspects  
of patient information should be addressed in the  
unit-based pharmacotherapy plan: 
1) supporting the patient’s participation and adherence
2) providing information
3) oral and written advice and guidance 
4) ensuring advice and guidance has been understood 
5) reporting any deviations occurring during treatment. 
Institutional care and home care mainly involve patients 
with chronic conditions who need long-term medication. 
Their prescriptions are renewed by a physician, and the 
unit or home care personnel pick up the medicines from 
the pharmacy. Those providing pharmacotherapy are thus 
responsible for ensuring that patients receive enough 
information about their medicines. Those providing phar-
macotherapy must have easy access to information on 
medicines in real-life situations, including when no Inter-
net connection is available (for example, in the home of 
an elderly patient). They must be able to obtain support 
for pharmacotherapy problems, for instance from the 
local pharmacy. 
when pharmacotherapy is provided in atypical settings, 
such as nurseries and schools, the emphasis is on  
collaboration with healthcare professionals and mutual 
agreements. In a nursery or school setting, an employee 
with no basic pharmacotherapy education may agree to 
participate in the pharmacotherapy of, for instance, a 
child’s chronic condition such as asthma or diabetes.  
In such cases, the employee must undergo additional 
training, permission must be obtained from the physician 
in charge (e.g. the school healthcare physician) and an 
agreement must be made between the parents, the  
employee providing the pharmacotherapy and the unit’s 
management (Ministry of Social Affairs and Health 2006). 
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Practical nurses may also participate in providing phar-
macotherapy in nurseries and schools, for instance when 
working as a school assistant or childcarer. Persons  
providing pharmacotherapy must receive adequate infor-
mation, particularly about the medicines in question. The 
unit-based pharmacotherapy plan describes how pharma-
cotherapy is carried out and how the necessary skills are 
ensured. It addresses both the provision of pharmaco-
therapy for children with chronic conditions and the use  
of medicines given for short periods and as required, 
such as antibiotics and painkillers.
Proposals:
• Ensure that units have unit-based pharmacotherapy 
plans that also include medicines information activities. 
• Ensure that persons providing pharmacotherapy have 
access to medicines information, for instance by:
- developing multidisciplinary cooperation with local 
stakeholders such as pharmacies;
- developing new tools and utilising new information  
and communication technologies (ICT) to support  
the provision of pharmacotherapy in social services 
and home care;
- utilising the networked services of institutions providing 
medicines information services, listed on page 13,  
in social service units and in atypical settings where 
pharmacotherapy is provided;
- assessing existing permit practices in atypical settings 
providing pharmacotherapy and using them to ensure 
the availability of key medicines information.
Ensuring medication counselling in self-care.
Today, patients are able to treat an increasing number of 
conditions or alleviate their symptoms on their own. The 
importance of self-care in treating symptoms and mild 
conditions has increased and continues to do so, for 
instance because of limited healthcare resources, the 
higher level of education among the population, an em-
phasis on patients taking responsibility for their treatment, 
and the wider range of over-the-counter (OTC) medicines 
available. In fact, the majority of symptoms are self-treated 
at home without any contacts with healthcare professionals. 
Appropriate self-care and self-medication mean savings 
for both the patient and society. According to one estimate, 
a 10% reduction in health centre visits achieved through 
self-care would result in annual public savings of  
€ 63 million (Pappila 2008). 
For the self-care patient, the pharmacy is often the only 
contact with the healthcare system. One of the most 
important functions of a pharmacy is to advise and  
counsel patients with regard to self-care and the need  
to seek medical care. Counselling concerning the use  
of OTC medicines is also an important part of pharmacy 
activities. Since April 2011, OTC medicines have also 
been available via pharmacy service points and online 
pharmacy services. According to the Medicines Act 
(1112/2010, section 57), when supplying medicinal  
products from pharmacy service points and via online 
pharmacy services, pharmacies must ensure that medici-
nal product purchasers have access to the advice and 
guidance of pharmaceutical personnel on the correct and 
safe use of medicinal products and to information about 
medicinal product prices and other factors affecting their 
choice of medicinal product. 
Physicians and nurses inform patients about the impor-
tance of a healthy lifestyle, including nutrition and exer-
cise, in the treatment of symptoms. Many pharmacies 
also provide guidance and support for things such as 
quitting smoking or losing weight. Physicians may also 
advise patients on how self-care affects the patient’s 
medication as a whole if the use of certain OTC medi-
cines or herbal medicinal products is not recommended 
because of a risk of interaction. Other healthcare profes-
sionals may also play a significant role in guiding self-
care. Physiotherapists, for example, may have a central 
role in the self-care of pain associated with musculoskel-
etal complaints. 
In order to take self-care and self-medication into account 
in the patient’s treatment as a whole, physicians and 
nurses must be familiar with OTC products and the way 
in which pharmacies advise patients in their use. All par-
ties involved must be aware of the treatment as a whole 
(including the use of OTC products and other prepara-
tions); one way to achieve this is to record the data on  
a medicines card. Pharmacies, health centres, child and 
maternity health clinics, maternity clinics and home care 
for the elderly should all use the same treatment guide-
lines and products and give the same advice (Ministry of 
Social Affairs and Health 2011b). Providing support for 
self-care requires both multidisciplinary cooperation and 
the appropriate tools. 
In future, self-care should be increasingly incorporated 
into healthcare as presented in the goals of the Medicine 
Policy 2020 (Ministry of Social Affairs and Health 2011a). 
when compiling the self-care programme, collaboration 
between pharmaceutical and healthcare services in sup-
porting self-care should be addressed on a national level.
Proposals:
• Support the work of professionals by producing  
evidence-based treatment guidelines concerning  
self-medication and self-care and integrate these  
into existing treatment guidelines wherever possible.
• Incorporate guidance for self-care and self-medication 
into the national self-care programme.
• Assess and monitor the quality of medicines information 
and medication counselling available from online  
pharmacy services and pharmacy service points.
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TO ENSURE THAT MEDICINE 
USERS UTILISE RELIABLE 
INFORMATION SOURCES 
AND SERvICES.
Ensuring the availability of reliable  
medicines information. 
The role of medicine users and patients has changed  
and is still changing from passive to active. Many sources 
of information are available for patients and the general 
public (Table 2). Participation in treatment decisions  
requires reliable and unbiased information, and the  
dissemination of such information to those needing  
medicines needs to be further improved. For instance,  
it is important to support patient organisations as they 
work to disseminate medicines information and to cooperate 
with these organisations to produce targeted information 
for specific patient groups. 
Proposal:
• Increase collaboration between patient organisations 
and other stakeholders in this field to improve  
medicines information.
Table 2. Examples of patients’ sources of information
Party producing or  
disseminating information
Information source
Physicians, nurses Medication counselling,  
patient guidance
Pharmacies, pharmacists Medication counselling, customer 
magazine Terveydeksi!
Finnish Medical  
Society Duodecim
Terveyskirjasto.fi website
Patient versions of the Current Care 
guidelines
National Pharmaceutical 
Information Centre KLIK
Telephone, online and e-mail services
University Pharmacy  
information services
Telephone, online and e-mail services
Poison Information Centre 
Teratological Information 
Service
Telephone services
Finnish Medicines  
Agency Fimea
Package leaflets
List of interchangeable medicinal products 
Pharmaceutical  
Information Centre
Kodin Lääkeopas book
Lääkeinfo.fi
Finnish Generic Pharma-
ceuticals Association
Lääkeohje.fi
Pharmaceutical industry Package leaflets,  
patient information guides
Social Insurance  
Institution of Finland
Information on reimbursement,  
Medicinal Products Database
Patient organisations Magazines
Information and educational events
Peer support education
GOAL 5.
Promoting the readability and usability of 
package leaflets. 
Package leaflets are an important source of medicines 
information for patients (Närhi 2007, Närhi and Helakorpi 
2007). They must comply with the SPC, and information 
necessary for product use must be presented in a specific 
order (Finnish Medicines Agency 2010, Directive 2001/83/EC 
of the European Parliament and of the Council). Patients 
from the target group must give their opinions to ensure 
the leaflet is readable, clear and user-friendly. The Fimea 
Normative Guideline 1/2010 provides detailed instructions 
on compiling the labelling and package leaflet for a me-
dicinal product. Although instructions are given, leaflet 
usability may be poor. There may also be differences in 
the package leaflets of medicinal products with the same 
active substance, which is confusing for the patient. In 
July 2011, EMA revised its package leaflet compilation 
instructions (European Medicines Agency 2011). In future, 
the benefits of the medicine must be better presented, 
and information on its suitability for children must also  
be provided. 
The European Union is currently preparing a Directive  
as regards information to the general public on medicinal 
products subject to medical prescription that will clarify 
the role of the pharmaceutical industry in direct patient 
communication about prescription-only medicines  
(European Commission 2008/0256 [COD]). The proposals 
reviewed by the Commission retain the current ban on 
advertising prescription-only medicines and emphasise 
patient rights, benefits and safety. According to the pro-
posals, patients may only be given certain information on 
prescription-only medicines, e.g. labelling and package 
leaflet information, prices, information on clinical trials 
and instructions for use. The proposals also restrict avail-
able communication channels and set out the quality 
requirements that the information must meet. 
Proposal:
• Further enhance package leaflet readability and  
contents in the EU.  
Producing medicines information in minority 
languages and for other special groups. 
The Act on the Status and Rights of Patients (17 August 
1992/785, section 3) notes that the mother tongue,  
individual needs and the culture of the patient must be 
taken into account as far as possible in the patient’s care.  
In Finland, medicines information in Swedish can be 
obtained from package leaflets available via the Fimea 
FimeaWeb service, the Lääkeinfo.fi online service of the 
Pharmaceutical Information Centre and the Lääkeohje.fi 
online service of the Finnish Generic Pharmaceuticals 
Association. Patient versions of Current Care guidelines 
are also being translated into Swedish. To meet the rights 
of immigrants and others to obtain medication counselling 
in their mother tongue, both tools for healthcare profes-
sionals and material for patients are required. Pictograms 
might be one such tool. English-language material may 
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also be useful. Major immigrant languages include Russian, 
Estonian, English, Somali, Arabic and vietnamese. 
very few sources of medicines information are available 
for special groups. Package leaflets are available for the 
visually impaired in mp3 audio file format at the Lääkeinfo.fi 
online service of the Pharmaceutical Information Centre. 
However, not all those with visual impairment are able  
to use computers and search information independently 
online. Medicines information must therefore also be 
available in other formats suitable for the visually impaired, 
such as large print, Braille and audio recordings. Particular 
attention should be given to the accessibility of websites 
containing medicines information. Medicines information 
should also be provided for sign language users, for  
instance by translating material into sign language and 
making it available online.
Proposals:
• Produce medicines information in Swedish. 
• Produce medicines information for special groups  
(immigrants, deaf and hard of hearing, visually impaired, 
elderly, children, patients with public health problems).
Increasing the use of information and 
communications technology to disseminate 
medicines information. 
The importance of ICT in disseminating medicines infor-
mation will increase in the future. This is both a challenge 
and an opportunity for the healthcare system. New tech-
nological innovations may help patients to use medicines 
in daily life (e.g. reminders, technologically advanced 
packaging) and also help in providing patients with  
medicines information specific to their needs. Electronic 
healthcare services provide electronic information trans-
fers, for instance between patients and healthcare service 
providers. The range of available applications is large  
and extends from electronic patient records systems and 
appointments systems to telemedical services and port-
able patient monitoring devices. The development of ICT 
technologies will encourage patients and medicine users 
to take greater responsibility for their own treatment. 
There is plenty of reliable medicines information for  
patients online, an example being the Terveyskirjasto.fi 
health library site maintained by the Finnish Medical Society 
Duodecim. However, not all online information is reliable 
or unbiased. Online discussion forums in particular  
contain plenty of discussions on current matters related  
to medicines. They are often based on individual experi-
ences, and the writers may not have understood the fact 
that pharmacotherapies are tailored individually. Pharma-
ceutical companies display on their websites information 
and patient information leaflets concerning their propri-
etary products. To help people find and identify reliable 
medicines information, reliable medicines information 
sources that meet predefined criteria could be collected 
on a single site through which patients could also report 
adverse effects. A quality label would be another option. 
The Ministry of Finance eServices and eAdministration 
project (SADe) involves plans for a project to gather  
general social affairs and health information and make  
it available to citizens and local authorities. The aim is  
to use such general information to compile a shared 
knowledge base available on the websites of local  
authorities and accessible to everyone, particularly the 
customer advisors of local authorities. This would support 
citizens in their use of electronic services and communi-
cations. Information would be produced by e.g. organisa-
tions in the Ministry of Social Affairs and Health adminis-
trative sector, each organisation being responsible for 
covering its own sphere of competence. Patient-specific 
information in the National Archive of Health Information’s 
ePrescription system should also be linked to general 
information on the medicines currently used by the patient. 
Patients use the Internet for a number of purposes, not 
just to seek factual information. They also look for peer 
support and treatment experiences by other medicine 
users (Pohjanoksa-Mäntylä 2010). Healthcare service 
providers should take this into account, for instance by 
providing discussion forums in which healthcare profes-
sionals are present to ensure the information is reliable.
Proposals:
• Incorporate general medicines information for citizens 
into other social affairs and healthcare information in  
the SADe project. 
• Link general medicines information, including  
information on medicines currently used by the  
patient, to patient-specific information in the National 
Archive of Health Information’s ePrescription system.
• Create a list of links to reliable sources of medicines 
information or establish a quality label.
• Develop and promote the visibility and participation  
of healthcare professionals in social media. 
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TO ACHIEvE A HIGH  
LEvEL OF HEALTH  
LITERACY AMONG  
THE GENERAL PUBLIC. 
Promoting health literacy among  
children and adults.
A large amount of medicines information is currently 
available to the public. However, it is not easy to assess 
whether the information is reliable and unbiased. Promoting 
health literacy among the public has therefore been con-
sidered to be a challenge both internationally (High Level 
Pharmaceutical Forum 2008) and in Finland (Ministry of 
Social Affairs and Health 2011a). In addition to improving 
the population’s skills to seek information and assess its 
reliability, greater self-confidence and skills are required 
when making health and lifestyle decisions (Nutbeam 
1998, Paakkari and Paakkari 2012). It is therefore impor-
tant to encourage clients and patients to seek information 
and discuss their medication with healthcare professionals. 
A number of tools have been developed to help in assessing 
the reliability of medicines information. These include the 
DARTS checklist (Närhi et al. 2008), the use of which 
should be promoted. The dissemination of information  
on falsified medicines and the risks of medicines ordered 
online should also be continued, for instance by means of 
population-level campaigns such as those required by the 
Falsified Medicines Directive (Directive 2011/62/EC of the 
European Parliament and of the Council).
Population-level campaigns may also be used to increase 
awareness of the correct use of medicines. The campaign 
could include the following, which are relevant for both 
medicine and medication safety:  
• The difference between medicines and other  
products, e.g. nutritional supplements.
• Individual differences in how people react  
to medicines.
• Potential differences between generic preparations.
The campaign should address different target groups 
(different messages and communication media are  
required to reach both young people and the elderly) 
and special groups such as the visually impaired and  
the deaf. In addition to increasing awareness, promoting 
local cooperation between healthcare stakeholders 
should be an important goal. To be worthwhile, the  
campaign should therefore take the form of multidisci-
plinary collaboration between a number of stakeholders 
to achieve wide visibility.
GOAL 6. The development of health literacy skills should start in childhood. School health education allows educators to 
reach the entire cohort of Finnish children of a specific 
age. According to the national Core Curriculum, medi-
cines education, i.e. education on the appropriate use  
of medicines, should be included in environmental and 
natural sciences in primary school and in health educa-
tion in lower secondary school (Finnish National Board 
of Education 2004). However, teachers may be unfamiliar 
with matters related to medicines and may need training 
to be able to deliver teaching consistent with the Core 
Curriculum. Teaching may also be organised jointly by 
inviting a school health nurse or pharmacist to give  
medicines education lessons during health education 
classes. The Core Curriculum contains a large amount 
of material for the number of hours available, and medi-
cines education is a small part of health education. 
Health education currently focuses on warning against 
medicine abuse, which may result in children starting  
to fear medicines. In future, it is important to motivate 
and advise teachers to talk about the appropriate use of 
medicines as such and avoid linking the matter to abuse 
issues. The medicines education web pages compiled 
by the University of Eastern Finland School of Pharmacy 
can be used in teaching as a supplement to course-
books. It is important that these pages are maintained 
and updated.  
Proposals:
• Promote the use of the DARTS checklist, developed to 
help assess whether medicines information is reliable, 
among the public and in school teaching. 
• Carry out a multidisciplinary population-level campaign 
on the safe and appropriate use of medicines.
• Update medicines information webpages to produce  
a generic source of medicines information for the  
general public.
• Ensure that the appropriate use of medicines and  
medicines information literacy continue to be included  
in the Core Curriculum for basic education. 
- Create national medicines education guidelines for 
schools in which the appropriate use of medicines  
is integrated into a wider educational context.
- Encourage medicines education collaboration between 
schools and the healthcare system and develop guide-
lines and material to support healthcare professionals 
giving medicines education lessons.
- Ensure teaching material is provided for special 
groups such as sign language users.
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Fimea’s participation in the development of the medicines information proposals
Fimea has examined the proposals in the Medicines Information Strategy that are clearly within its scope of activities or that  
it could consider carrying out subject to further investigations (Table 3).
Table 3. Fimea’s participation in the development of the medicines information proposals
Proposal Fimea’s contribution
Establish a medicines information network in order to increase  
cooperation, a more systematic approach and greater multidisciplinarity 
in developing medicines information activities and to promote  
collaboration between the public and private sectors.
Fimea will coordinate the activities of the medicines information network.
Produce summaries of pharmacotherapies  
(such as the Kapseli publication series).
Fimea will assess the need to compile new Kapseli publications  
and update past issues together with the Social Insurance Institution.
Fimea will publish summaries of new approved medicines in its  
publication Sic!
Produce evaluations and summaries of the therapeutic and economic 
value of medicines for healthcare professionals and patients. Encourage 
greater utilisation of evaluated evidence.
Fimea will produce evaluations of the therapeutic and economic value 
of medicines in collaboration with other stakeholders, based on agreed 
guidelines.
Improve the availability of medicines information in Swedish for  
healthcare professionals. 
Fimea will also produce medicines information in Swedish.
Establish an effective information management system for crisis  
situations and pharmacovigilance-related information to ensure that  
all healthcare professionals can be contacted during the same day.
Fimea will increase collaboration with other stakeholders with regard  
to providing information in crisis situations.
Ensure easy access to SPCs. Improve the quality of SPCs in the EU. Fimea will participate in improving SPC quality in the EU.
Fimea will develop its website to allow easy access to SPCs  
(including those for products approved via the centralised procedure) 
based on the brand name or generic name in Finnish.
Evaluate opportunities for networking and coordination of activities 
between the stakeholders currently providing medicines information 
services. 
If necessary, Fimea will coordinate the evaluations.
Evaluate and monitor the quality of medicines information disseminated 
by stakeholders providing medicines information services.
Fimea will produce an evaluation of the quality of medicines information 
disseminated by stakeholders providing medicines information services.
Increase awareness of and collaboration between Clinical Pharmacology 
and Clinical Pharmacy services.
• Develop Clinical Pharmacology and Clinical Pharmacy services and 
ensure access to them everywhere in Finland, for instance by creating 
a network-type consultation service for healthcare professionals.
• Shift the focus of ward pharmacy activities from medicine logistics 
towards clinical pharmacy: medication review and medication  
counselling for patients (e.g. admission interview, review of admitted 
patients’ medication, medication counselling on discharge together  
with a physician and a nurse).
Fimea will address the need to develop clinical pharmacology, clinical 
pharmacy and ward pharmacy activities in a collaborative project to cre-
ate national guidelines for multidisciplinary work.
Define quality and structural standards for medication counselling and 
assess the possibility to document and monitor medication counselling.
Fimea will establish a working group and coordinate its activities.
Incorporate guidance for self-care and self-medication into the national 
self-care programme.
Fimea will participate in compiling a self-care programme including  
ways to ensure medication counselling in self-care and self-medication.
Assess and monitor the quality of medicines information and  
medication counselling available from online pharmacy services  
and pharmacy service points.
Fimea will monitor the quality of medicines information and medication 
counselling as part of its pharmacy inspections. It will also carry out  
a more extensive review.
Increase collaboration between patient organisations and other  
stakeholders in this field to improve medicines information.
Fimea will increase collaboration with patient organisations.
Further enhance package leaflet readability and contents in the EU. Fimea will participate in improving package leaflet quality in the EU.
Create a list of links to reliable sources of medicines information or 
establish a quality label.
Fimea will assess the opportunities to evaluate reliable sources  
of medicines information. This assessment will then be used to  
decide whether Fimea will maintain a website or a list of links to  
reliable sources of information.
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Promote the use of the DARTS checklist, developed to help assess  
whether medicines information is reliable, among the public and in  
school teaching. 
Fimea will utilise the checklist and promote its use wherever possible,  
for instance via campaigns intended for the general public.
Carry out a multidisciplinary population-level campaign concerning the 
appropriate use of medicines.
Fimea will participate in carrying out a multidisciplinary population-level 
campaign, if relevant.
Update medicines information webpages to produce a generic source of 
medicines information for the general public.
Incorporate general medicines information for citizens, produced by Fimea, 
in other general social affairs and healthcare information in the SADe 
project.
Ownership and control of webpages produced by the University of  
Eastern Finland School of Pharmacy will be transferred to Fimea. In con-
nection with this, Fimea will update the website and transform it  
into a source of generic medicines information for the general public.  
The site contents will be used in the SADe project in the form of  
general medicines information.
Create national medicines education guidelines for schools in  
which the appropriate use of medicines is integrated into a wider  
educational context.
• Encourage medicines education collaboration between schools and 
the healthcare system and develop guidelines and material to support 
healthcare professionals giving medicines education lessons.
Fimea will be one of the partners in a research project by the University 
of Eastern Finland School of Applied Educational Science and Teacher 
Education and the School of Pharmacy. The project will seek to produce 
recommendations on how to integrate information on the appropriate  
use of medicines into a wider educational context in primary and  
secondary schools.
Table 3 continuing. Fimea’s participation in the development of the medicines information proposals
25
ANNEXES
ANNEX 1. Organisations that participated in preparing the Medicines Information Strategy
Public administration
Association of Finnish Local and Regional Authorities
Finnish Medicines Agency Fimea
Ministry of Social Affairs and Health
Social Insurance Institution of Finland
Trade and professional unions and organisations
Association of Finnish Pharmacies
Finnish Medical Association
Finnish Nurses Association
Finnish Pharmacists’ Association
Finnish Union of Practical Nurses
Finnish Pharmacists’ Society
Union of Health and Social Care Professionals Tehy
Scientific societies
Finnish Medical Society Duodecim
Finnish Society of Clinical Pharmacology
Finnish Society of Clinical Pharmacy
Pharmaceutical industry organisations
Finnish Generic Pharmaceutical Association
Pharma Industry Finland
University pharmacies
University of Eastern Finland Pharmacy
University Pharmacy
Universities, polytechnics, vocational institutions 
and complementary education units
Pharmaceutical Learning Centre
Savonia University of Applied Sciences
Savo vocational College
Turku University of Applied Sciences
University of Eastern Finland, Aducate Centre for Training and Development
University of Eastern Finland, Faculty of Health Sciences
University of Helsinki, Faculty of Medicine
University of Helsinki, Faculty of Pharmacy
University of Helsinki, Palmenia Centre for Continuing Education
University of Tampere, School of Medicine
University of Turku, Faculty of Medicine 
Åbo Akademi, Unit of Pharmaceutical Sciences
Hospitals, hospital pharmacies and dispensaries
City of Lahti social and health services, hospital pharmacy
HUS Pharmacy
Kuopio University Hospital
Kuopio University Hospital, hospital pharmacy
varkaus Hospital, dispensary
Companies offering pharmaceutical services
DRA Consulting Oy
Farenta Oy
Pro Dosis Oy
Companies producing medicines information
Pharmaceutical Information Centre
Patient associations and organisations
Allergy and Asthma Federation 
Association of voluntary Health, Social and welfare Organisations
Finnish Association of the Deaf
Finnish Diabetes Association
Finnish Federation of the visually Impaired
Finnish Heart Association
Finnish Kidney and Liver Association
Finnish Migraine Association
Finnish Osteoporosis Association
Finnish Rheumatism Association 
Pääkaupunkiseudun Osteoporoosiyhdistys  
      (‘Metropolitan Area Osteoporosis Association’)
Suomen Nivelyhdistys (‘Finnish joint Association’)
Suomen Potilasliitto (‘Finnish Patient Association’)
Thyroid Foundation of Finland
Student associations and organisations
Tehyn opiskelijayhdistys ry  
      (‘Students’ Association of the Union of Health and  
        Social Care Professionals Tehy’) 
Finnish Pharmaceutical Students’ Association FiPSA  
Finnish Medical Students’ Association
Sairaanhoitajaliiton opiskelijajärjestö  
      (‘Students’ Association of the Finnish Nurses Association’)
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ANNEX 2. Examples of medicines information  
sources for healthcare professionals  
Party producing or disseminating information Information source
Authorities
Social Insurance Institution of Finland Statistics on the use of medicines reimbursed from health insurance funds
Kapseli publications (together with Fimea)
Medicinal Products Database
Finnish Medicines Agency Fimea SPCs and package leaflets
Medicine consumption statistics
Medicines classification (ATC-DDD)
Database of medication for the elderly
Database on medicinal products available for compassionate use
List of interchangeable medicinal products
The journal Sic! Drug information from Fimea
Pharmacovigilance-related information 
Other publications and publication series, including the Kapseli publications in collaboration  
with the Social Insurance Institution
Public and professional bodies
Finnish Medical Society Duodecim The Terveysportti portal and its specialised databases:
• Duodecim Lääketietokanta medicines database
• SFINX
• Renbase
• Gravbase, Lactbase
• Herbalbase
• Lääkkeen vaikutus laboratoriotutkimuksiin (Drug Laboratory Effects) database
• Physicians’ and nurses’ databases
Current Care guidelines
Evidence-Based Medicine electronic Decision Support (EBMeDS) system
Poison Information Centre
Teratology Information Service
Telephone services
Hospital pharmacies Solving problems related to pharmacotherapies
Instructions concerning pharmacotherapies
Information on medicines consumption, new guidelines, product defects etc.
Hospital districts Instructions concerning pharmacotherapies
Association of Finnish Pharmacies The Tietotippa, Salvia and Salko databases
Clinical Pharmacology units at  
university hospitals and universities
Solving challenging patient-specific problems in university hospitals (consultation service)
Producing information on pharmacotherapies, e.g. coursebooks 
Organisations and associations in  
different fields
Scientific publications (e.g. Duodecim Medical Journal)
Professional publications (e.g. the Lääkeinfo pages in the Finnish Medical journal)
National guidelines compiled by specialist societies
Private stakeholders
National Pharmaceutical Information  
Centre KLIK
Telephone, online and e-mail services, documented reply database
Pharmaceutical Information Centre Pharmaca Fennica®
Medicines lists
Pharmaceutical companies Information on specific medicinal substances and products
SPC and package leaflet
Medical information services
University Pharmacy University Pharmacy HELP texts, information services
27
ANNEX 3. Multidisciplinary collaboration methods in monitoring self-management and long-term 
treatment (Ministry of Social Affairs and Health 2011b, Peura et al. 2007)
Type of collaboration Contents Responsibilities
Medication assessment • Assessment of an individual patient’s medication, the 
need for it and its appropriateness as part of a normal 
patient examination and treatment planning.
• A physician makes an assessment.
• Other healthcare professionals assist the  
physician, if necessary.
Prescription renewal • In the guidelines for prescription renewal (Lahnajärvi 
2006), the emphasis is on treatment follow-up: 
1) submitting a prescription for renewal,  
2) receiving and preparing the prescription,  
3) checking the renewal,  
4) producing the prescription,  
5) signing the prescription, 
6) recording prescription renewals and  
7) picking up the prescription.
• Renewal practices are discussed in meetings to  
review particular problem areas such as:
 - medicines not renewed without an appointment
 - patients with chronic conditions and polypharmacy
 - centrally acting substances and other medicines  
   with abuse potential
 - medicine abusers.
• A nurse (at appointments) or a pharmacist (at a  
pharmacy) receives the prescription, asks when the 
patient last had a medical check-up and when the  
next one is due, and asks the patient’s opinion about 
the effectiveness and use of the medicine and any 
problems associated with it. The nurse or pharmacist 
also prepares the prescription for renewal.
• The physician treating the patient or renewing the 
prescription or a nurse prepares the renewal entries  
or, if necessary, issues a new prescription form by 
hand or on computer.
• Before renewal, the physician treating the patient or 
renewing the prescription checks whether a renewal 
is required and reviews the duration of the therapy 
and any interactions. The physician signs the renewal 
entries and puts a stamp on the prescription.
• A clinic assistant enters any manually renewed  
prescriptions in patient records. Computer  
prescriptions are entered automatically.
• A nurse (at appointments) or a pharmacist  
(at a pharmacy) gives the prescription and  
any associated messages to the client.
Electronic prescription  
renewal (National Archive  
of Health Information, 2011)
• The use of electronic  
prescriptions is based  
on a centralised national  
database known as the 
Prescription Centre.
• For each electronic pre-
scription, the Prescription 
Centre records data on 
who has viewed, changed 
or otherwise processed the 
prescription or cancelled it 
and the time when this took 
place (Act on Electronic 
Prescriptions, 61/2007).  
• The patient or a person acting on the patient’s behalf 
may request to have the electronic prescription renewed 
by phone, by visiting a healthcare unit or during other 
contacts with a healthcare unit or pharmacy.
• Renewal requests may also be submitted via an  
electronic health service requiring reliable  
identification.
• The pharmacy sends the renewal request to the  
Prescription Centre, which transfers the request  
automatically to the healthcare unit indicated by  
the patient.
• A prescription may only be renewed if no more  
than 16 months have passed since the original  
prescription was issued.
• Prescriptions with refills and those for narcotics or 
centrally acting substances may also be renewed.
• Patients cannot determine which physician in the 
organisation will receive and process the renewal 
request.
• The Prescription Centre considers a renewal request 
to have expired if it has not been processed at a 
healthcare unit within 8 days of the renewal request 
being submitted to the patient records system.
• If a renewal request expires, a new renewal request 
may be submitted for the same prescription.
• Healthcare units cannot be requested to renew a 
rejected prescription.
• If a patient wishes, the results of a renewal request 
may be sent by SMS.
• The renewal request may also contain a message  
to the physician.
• If a patient’s prescription is not renewed for therapy-
related reasons and the patient has not requested an 
SMS notification, the healthcare unit must inform the 
patient that the request was rejected by some other 
means, e.g. by phone or mail.
• Each healthcare unit lists the employees who have  
the right to receive renewal requests.
• The right to process renewal requests in the patient 
records system may also be given to a person who  
is not a healthcare professional.
• Those processing renewal requests must have  
an authentication card issued by a healthcare  
authenticator to log on to the patient records system.
• A renewal request may also be received by a physician 
who did not issue the original prescription.
• The physician who received the renewal request  
has the right to download the prescription from the  
Prescription Centre without the separate consent of 
the patient.
• A physician may either approve, reject or return the 
renewal request.
1) To approve it, the physician issues a new  
prescription on the basis of the old one and  
sends it to the Prescription Centre. 
2) If a physician does not renew the prescription,  
he or she records in the system that the request 
was rejected. 
3) If the renewal request is not to be renewed by the 
organisation in question and it is being processed 
by a physician, the physician may return it in the 
same way as those processing renewal requests do.
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Medication review • A healthcare professional checks that the dosage  
and administration times of the patient’s medication 
are consistent with accepted treatment practice.  
The same person also checks for any overlaps  
and incompatibilities.
• This review is part of the normal dispensing of  
medicines in pharmacies and distribution on wards  
or in connection with home nursing.
• Pharmacies also perform the review when  
dispensing OTC medicines.
• A medication review does not involve an  
assessment of therapeutic indications or the  
need for pharmacotherapy.
• A healthcare professional (a physician, nurse,  
pharmacist) checks that the dosage and administration 
times of the patient’s medication are consistent with 
treatment guidelines. The same person also checks  
for any overlaps and incompatibilities.
• The physician treating the patient decides on any 
changes to the patient’s medication and is responsible 
for the patient’s pharmacotherapy and its follow-up.
Dose dispensing • The patient’s medication is reviewed, and the  
list of medicines being used is updated.
• The medicines are divided into doses either  
manually or by machine.
• A check is then made to ensure that the  
medicines have been divided correctly.
• The medicines are dispensed to the patient in  
unit dose bags.
• A pharmacist reviews the patient’s medication.
• A physician decides on any medication changes  
recommended by a pharmacist.
• The pharmacy is responsible for ensuring that the 
contents of the order and the contents of the  
medicine doses dispensed to the patient are correct.
• A pharmacist is responsible for updating the  
patient’s medicine list and giving it to the patient.
• If necessary, home care or home nursing personnel 
administer the medicines to the patient.
Comprehensive  
medication review
• To perform a comprehensive medication review, suf-
ficient background details (age, sex, conditions and 
their treatment, previous medication, current status, 
nutrition, exercise, smoking, alcohol) are obtained from 
the following sources:
- interview with the patient (if necessary,  
relatives or nursing personnel)
- patient records
- laboratory records.
• In a comprehensive medication review, the need  
and therapeutic indications for pharmacotherapy are 
assessed, as are any adverse effects, interactions,  
the effects of age on pharmacotherapy, inappropriate 
or symptomatic medication, medication overlaps, dos-
ages and administration times and the reimbursement 
status and economic aspects of pharmacotherapy.
• The information collected is analysed, and the  
problem being addressed is solved.
• After the comprehensive medication review,  
a written report is compiled. This contains a list  
of the observations made and recommendations  
for the physician treating the patient.
• When the report is submitted, its contents are discussed 
with the patient and, if necessary, a physician or other 
persons or units treating the patient.
• Further measures and their effects on follow-up are 
assessed.
• Comprehensive medication reviews are performed by 
a pharmacist with the necessary formal qualifications. 
• The physician treating the patient decides on any 
changes to the patient’s medication and is responsible 
for the patient’s pharmacotherapy and its follow-up.
• Nursing professionals participate in the medication 
review and in medication follow-up as required and  
are involved in a multidisciplinary treatment team.
• Multidisciplinary consultation and collaboration are 
arranged during all stages of the process.
ANNEX 3 continuing. Multidisciplinary collaboration methods in monitoring self-management and 
long-term treatment (Ministry of Social Affairs and Health 2011b, Peura et al. 2007)
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